1. Home /
  2. Biotechnology

Biotechnology

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

The company says the test revealed patients were experiencing 'deepening and durability of response over time' with the treatment.

Amgen Shares Gain on Positive Lung-Cancer Trial Results

Amgen Shares Gain on Positive Lung-Cancer Trial Results

Shares of Amgen rise after the company announces positive initial trial results from its experimental drug used to treat non-small-cell lung cancer patients.

Teva Shares Rebound on Oppenheimer Upgrade

Teva Shares Rebound on Oppenheimer Upgrade

Shares of drugmaker Teva surge after receiving an upgrade from Oppenheimer, albeit with a reduced 12-month price target.

Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend

Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend

In the short run the stock of this biotech giant could bounce as momentum has slowed, but the bigger picture is for further weakness.

Cara Therapeutics Surges on Phase 3 Results for Itchiness Treatment

Cara Therapeutics Surges on Phase 3 Results for Itchiness Treatment

Cara Therapeutics surges after announcing positive results for treatment of kidney disease-related itchiness.

Teva Settles With Oklahoma Over Opioid Allegations

Teva Settles With Oklahoma Over Opioid Allegations

Israeli drugmaker says its payment of $85 million to the state is not an admission of wrongdoing; Johnson & Johnson subsidiary Janssen Pharmaceuticals meanwhile also defends company and says its open to a resolution.

These 3 Biotech Stocks Are Attracting Insider Buying

These 3 Biotech Stocks Are Attracting Insider Buying

What are insiders buying as the market sells off in recent trading sessions?

Mallinckrodt Tumbles After Filing a Lawsuit Against the HHS on Acthar Gel

Mallinckrodt Tumbles After Filing a Lawsuit Against the HHS on Acthar Gel

The drugmaker files suit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services in order to protect Medicaid patient access to its Acthar gel.

Merck to Acquire Peloton Therapeutics for About $1B in Cash

Merck to Acquire Peloton Therapeutics for About $1B in Cash

Merck agrees to buy privately held Peloton Therapeutics for $1 billion in cash, giving it access to Peloton's molecular therapy treatments for patients with cancer and other non-oncology diseases.

Merck's Keytruda Fails to Meet Goal in Breast Cancer Trial

Merck's Keytruda Fails to Meet Goal in Breast Cancer Trial

Merck says one of its key cancer-fighting drugs, Keytruda, failed to meet its stand-alone goal of treating an aggressive type of breast cancer.